Shares of Trevena, Inc. (NASDAQ:TRVN) traded down 4.7% on Monday . The company traded as low as $1.55 and last traded at $1.78. 1,279,300 shares changed hands during trading, an increase of 66% from the average session volume of 771,489 shares. The stock had previously closed at $1.70.

A number of analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $5.00 target price on shares of Trevena in a report on Monday. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Trevena in a report on Wednesday, November 8th. Needham & Company LLC reduced their target price on shares of Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Zacks Investment Research cut shares of Trevena from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, Barclays PLC cut shares of Trevena from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $15.00 to $2.50 in a report on Monday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. Trevena presently has a consensus rating of “Buy” and a consensus target price of $8.75.

The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.38.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.06. During the same quarter last year, the business posted ($0.57) earnings per share. equities research analysts anticipate that Trevena, Inc. will post -1.29 EPS for the current year.

A number of institutional investors have recently bought and sold shares of TRVN. Bank of New York Mellon Corp boosted its stake in Trevena by 40.4% in the 1st quarter. Bank of New York Mellon Corp now owns 231,553 shares of the biopharmaceutical company’s stock worth $851,000 after purchasing an additional 66,577 shares during the period. American International Group Inc. boosted its stake in Trevena by 7.1% in the 1st quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 1,816 shares during the period. Geode Capital Management LLC boosted its stake in shares of Trevena by 4.2% during the 1st quarter. Geode Capital Management LLC now owns 390,429 shares of the biopharmaceutical company’s stock valued at $1,432,000 after buying an additional 15,839 shares during the period. Tudor Investment Corp ET AL acquired a new stake in shares of Trevena during the 1st quarter valued at $202,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Trevena by 12.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 6,402 shares during the period. 57.71% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Trevena, Inc. (TRVN) Shares Down 4.7%” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/13/trevena-inc-trvn-shares-down-4-7.html.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.